C4XD C4X Discovery Holdings

EQS-News: C4X Discovery signs potential $402mln deal

EQS-News: C4X Discovery Holdings PLC
C4X Discovery signs potential $402mln deal

28.11.2022 / 15:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive

Proactive UK Ltd

3


News Source: News Direct

28.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: C4X Discovery Holdings PLC
United States
ISIN: GB00BQQ2RV18
EQS News ID: 1499599

 
End of News EQS News Service

1499599  28.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1499599&application_name=news&site_id=research_pool
EN
28/11/2022

Underlying

C4XDC4X Discovery Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C4X Discovery Holdings

 PRESS RELEASE
Free
C4XD C4X Discovery H...

C4X Discovery receives latest milestone payment from Sanofi

C4X Discovery receives latest milestone payment from Sanofi €8 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme 27 May 2025 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it has received a milestone payment of €8 million from Sanofi [EPA: SAN], reflecting further pre-clinical progress in the ongoing oral IL-17A inhibitor programme. This is the latest milestone payment from a license agreement between the two companies, which was first secured in April 2021. Under the terms of the deal, C4XD...

May 27, 2025 1 EN
 PRESS RELEASE
Free
C4XD C4X Discovery H...

PatientSeek identifies a genetic signature that separates a4b7 integri...

PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease C4X Discovery Holdings Limited PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease Progresses precision method for patient selection - the right patient for the right medicine 16 September 2024 - C4X Discovery Holdings Limited (“C4XD”), the immuno-inflammation therapeutics company, today announces the discovery of a genetic response signature t...

September 16, 2024 1 EN
 PRESS RELEASE
Free
C4XD C4X Discovery H...

C4X Discovery Holdings Limited announces progress on immuno-inflammati...

C4X Discovery Holdings Limited announces progress on immuno-inflammation programmes and appointment of new Board members C4X Discovery Holdings Limited C4XD announces progress on immuno-inflammation programmes and appointment of new Board members 22 July 2024 - C4X Discovery Limited (“C4XD”), a pioneering drug discovery company, today provides an update on the business following its delisting from AIM earlier in the year. Clive Dix, Executive Chairman of C4XD, said: “The great work at C4XD continues. We are utilising our strong capital position to drive forward our immuno-inflammatory po...

July 22, 2024 1 EN
Martin Hall
  • Martin Hall
SN. SMITH & NEPHEW ...
ETX E-THERAPEUTICS ... (+18)

Hardman & Co Insight: Survival of the UK life sciences sector

For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This is quite unusual for healthcare stocks. Apart from the general economic influences, which have made institutions more risk-averse, there was a common knowledge that several companies were in need of additional working capital; so, share prices were marked down in anticipation of equity raises. However, the small- and mid-cap life sciences sector has alway...

SN. SMITH & NEPHEW PLC
ETX E-THERAPEUTICS
AGY ALLERGY THERAPEUTICS PLC
AVO ADVANCED ONCOTHERAPY
YGEN YOURGENE HEALTH
ALNOV NOVACYT SAS
C4XD C4X DISCOVERY HOLDINGS
REDX REDX PHARMA
GDR GENEDRIVE
GSK GLAXOSMITHKLINE PLC
AZN ASTRAZENECA PLC
CTEC CONVATEC GROUP PLC
RENE RENEURON GROUP
0008964D INDIVIOR INC
IMCR IMMUNOCORE HOLDINGS ADS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
TRX TISSUE REGENIX GROUP PLC
06/25/24 June 25, 2024 1 EN
6ZA Zanaga Iron Ore...
SUH Sutton Harbour ... ... (+9)

Hybridan Small Cap Feast - 14 Dec 23

14th December 2023 Small Cap Team will take a break until Monday 8 January 2024 after this Friday 15th December. Merry Christmas to all our readers. @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be...

6ZA ZANAGA IRON ORE CO. LTD.
SUH SUTTON HARBOUR GROUP
PANR PANTHEON RESOURCES
C4XD C4X DISCOVERY HOLDINGS
DRV DRIVER GROUP
MMAG MUSICMAGPIE PLC
SAR SAREUM HOLDINGS PLC
ENSI ENSILICA PLC
CEL CELADON PHARMACEUTICALS PLC
12/14/23 December 14, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch